

Richard M Goldberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7328363/publications.pdf>

Version: 2024-02-01

136
papers

28,292
citations

46918

47
h-index

21474

114
g-index

137
all docs

137
docs citations

137
times ranked

28895
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015, 372, 2509-2520.	13.9	7,696
2	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	6.0	4,945
3	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2013, 381, 303-312.	6.3	2,276
4	A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 23-30.	0.8	2,112
5	Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. <i>New England Journal of Medicine</i> , 2003, 349, 247-257.	13.9	1,962
6	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2392.	3.8	670
7	Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2005, 23, 8664-8670.	0.8	607
8	Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08. <i>Journal of Clinical Oncology</i> , 2011, 29, 11-16.	0.8	551
9	Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, 464.	3.4	510
10	Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803. <i>Journal of Clinical Oncology</i> , 2007, 25, 3456-3461.	0.8	423
11	Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1383.	3.8	412
12	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology</i> , The, 2015, 16, 937-948.	5.1	286
13	Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes. <i>Gastroenterology</i> , 2015, 148, 88-99.	0.6	273
14	Impact of primary (1 st) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3504-3504.	0.8	249
15	Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3385-3390.	0.8	244
16	Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. <i>Journal of Clinical Oncology</i> , 2019, 37, 1217-1227.	0.8	234
17	Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 3664-3672.	0.8	233
18	End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 4569-4574.	0.8	220

#	ARTICLE	IF	CITATIONS
19	The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer. <i>Oncologist</i> , 2007, 12, 38-50.	1.9	218
20	Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 3347-3353.	0.8	205
21	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 305-343.	157.7	203
22	Prognostic Value of <i>BRAF</i> and <i>KRAS</i> Mutations in MSI and MSS Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw272.	3.0	201
23	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with <i>KRAS</i> wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA3-LBA3.	0.8	178
24	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. <i>Molecular Cancer Research</i> , 2018, 16, 805-812.	1.5	169
25	Patient and Tumor Characteristics and <i>BRAF</i> and <i>KRAS</i> Mutations in Colon Cancer, NCCTG/Alliance N0147. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	140
26	DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG) Tj ETQq0 0 0 rgrBT /Overlock 10 Tf 5	3.0	136
27	Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 806.	3.4	136
28	<i>KRAS</i> Codon 12 and 13 Mutations in Relation to Disease-Free Survival in <i>BRAF</i> "Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance). <i>Clinical Cancer Research</i> , 2014, 20, 3033-3043.	3.2	129
29	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 144-150.	0.8	116
30	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 379.	3.4	104
31	Relationship between <i>MLH1</i> , <i>PMS2</i> , <i>MSH2</i> and <i>MSH6</i> gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. <i>International Journal of Cancer</i> , 2020, 147, 2948-2956.	2.3	102
32	Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. , 1996, 77, 1284-1291.		100
33	Racial Differences in <i>BRAF</i> / <i>KRAS</i> Mutation Rates and Survival in Stage III Colon Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv186.	3.0	98
34	Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in <i>MSH6</i> and <i>PMS2</i> . <i>Nature Communications</i> , 2017, 8, 14755.	5.8	96
35	Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance). <i>Clinical Cancer Research</i> , 2013, 19, 6957-6966.	3.2	95
36	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. <i>Journal of Clinical Oncology</i> , 2015, 33, 22-28.	0.8	87

#	ARTICLE	IF	CITATIONS
37	Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741. <i>Journal of Clinical Oncology</i> , 2011, 29, 1599-1606.	0.8	85
38	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 642-651.	0.8	84
39	Association of DNA Mismatch Repair and Mutations in <i>BRAF</i> and <i>KRAS</i> With Survival After Recurrence in Stage III Colon Cancers. <i>JAMA Oncology</i> , 2017, 3, 472.	3.4	82
40	A flexible design for multiple armed screening trials. <i>Statistics in Medicine</i> , 2001, 20, 1051-1060.	0.8	81
41	Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). <i>Clinical Cancer Research</i> , 2015, 21, 5294-5304.	3.2	70
42	Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3338-3346.	0.8	69
43	Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016, 34, 192-192.	0.8	69
44	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA3-LBA3.	0.8	68
45	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3096-3103.	3.2	65
46	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , 2020, 5, e000682.	2.0	64
47	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Clinical Cancer Research</i> , 2020, 26, 5943-5951.	3.2	55
48	Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741. <i>Clinical Cancer Research</i> , 2008, 14, 8263-8269.	3.2	52
49	Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of Clinical Oncology</i> , 2019, 37, 2620-2631.	0.8	51
50	Programmed death-1 blockade in mismatch repair deficient colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 103-103.	0.8	50
51	Promising New Agents for Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 29.	1.3	46
52	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2019, 25, 7497-7505.	3.2	44
53	Early Detection of Toxicity and Adjustment of Ongoing Clinical Trials: The History and Performance of the North Central Cancer Treatment Group's Real-Time Toxicity Monitoring Program. <i>Journal of Clinical Oncology</i> , 2002, 20, 4591-4596.	0.8	37
54	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017, 35, 1929-1937.	0.8	37

#	ARTICLE	IF	CITATIONS
55	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. <i>European Journal of Cancer</i> , 2020, 140, 119-129.	1.3	37
56	Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa023.	1.4	36
57	Diagnosis of digestive system tumours. <i>International Journal of Cancer</i> , 2021, 148, 1040-1050.	2.3	36
58	Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative. <i>JCO Precision Oncology</i> , 2021, 5, 779-791.	1.5	31
59	Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. <i>Genetics in Medicine</i> , 2016, 18, 863-868.	1.1	30
60	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. <i>Oncologist</i> , 2019, 24, 319-326.	1.9	29
61	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 404-413.	1.9	25
62	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1693-1704.	3.0	25
63	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3234-3242.	3.2	24
64	Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3003-3003.	0.8	24
65	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435.	3.0	24
66	Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. <i>Cancer</i> , 2018, 124, 3118-3126.	2.0	23
67	Hypermutated Tumors and Immune Checkpoint Inhibition. <i>Drugs</i> , 2018, 78, 155-162.	4.9	22
68	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz078.	1.4	22
69	UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. <i>Investigational New Drugs</i> , 2013, 31, 1559-1567.	1.2	21
70	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. <i>Oncogene</i> , 2021, 40, 4894-4905.	2.6	19
71	Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2146-2154.	1.9	18
72	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. <i>European Journal of Cancer</i> , 2021, 144, 101-112.	1.3	18

#	ARTICLE	IF	CITATIONS
73	Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54 Suppl 1, S57-64.	1.1	17
74	Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405. <i>Clinical Colorectal Cancer</i> , 2013, 12, 95-102.	1.0	17
75	Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. <i>International Journal of Cancer</i> , 2016, 139, 986-995.	2.3	16
76	Comprehensive Analysis of R-Spondin Fusions and <i>RNF43</i> Mutations Implicate Novel Therapeutic Options in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1863-1870.	3.2	16
77	2010 Staging System for Colon and Rectal Carcinoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 1513-1517.	0.7	14
78	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2634-2640.	1.9	14
79	Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients: A pooled analysis of three adjuvant trials. <i>European Journal of Cancer</i> , 2022, 166, 100-111.	1.3	13
80	How we treat metastatic colon cancer in older adults. <i>Journal of Geriatric Oncology</i> , 2013, 4, 295-301.	0.5	11
81	Adjuvant chemotherapy for colon cancer. <i>Current Oncology Reports</i> , 2001, 3, 94-101.	1.8	10
82	Primary Tumor Sidedness as Prognostic and Predictive Biomarker in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, 165.	3.4	10
83	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020, 12, 1319.	1.7	10
84	Update on Anti-angiogenesis Therapy in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 378-387.	1.0	9
85	Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147. <i>Journal of Clinical Oncology</i> , 2014, 32, 3525-3525.	0.8	9
86	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , 2021, 5, 95.	2.3	9
87	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa024.	1.4	8
88	Association of tumor infiltrating lymphocytes (TILs) with molecular subtype and prognosis in stage III colon cancers (CC) from a FOLFOX-based adjuvant chemotherapy trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 3518-3518.	0.8	8
89	Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2717-2723.e3.	2.4	7
90	Molecular landscape of colorectal cancers harboring R-spondin fusions. <i>Journal of Clinical Oncology</i> , 2019, 37, 3588-3588.	0.8	7

#	ARTICLE	IF	CITATIONS
91	Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?. <i>Oncotarget</i> , 2015, 6, 22206-22213.	0.8	7
92	Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. <i>Oncogene</i> , 2022, 41, 260-267.	2.6	7
93	How Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 372-379.	1.0	6
94	Highlights in Gastrointestinal (Colorectal) Cancer Treatment. <i>JAMA Oncology</i> , 2016, 2, 1537.	3.4	6
95	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa074.	1.4	6
96	Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1349-1358.	1.1	6
97	Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3507-3507.	0.8	6
98	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 60-67.	3.0	5
99	Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 275-275.	0.8	5
100	Reply to J.N. Primrose et al and C.-H. KÅrthne. <i>Journal of Clinical Oncology</i> , 2015, 33, 2408-2409.	0.8	4
101	Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab070.	1.4	4
102	Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3520-3520.	0.8	4
103	Impact of overall severity of adverse events (AEs) on long-term outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line systemic chemotherapy: Findings from 3,971 pts in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3582-3582.	0.8	4
104	Association of Homologous Recombinationâ€DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 227-236.	1.9	4
105	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	1.4	3
106	Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3590-3590.	0.8	3
107	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	3
108	Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months.. <i>Journal of Clinical Oncology</i> , 2015, 33, 710-710.	0.8	2

#	ARTICLE	IF	CITATIONS
109	Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, S23-7.	0.8	2
110	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	3.0	2
111	Colorectal clinical trials: what is on the horizon?. <i>Future Oncology</i> , 2016, 12, 525-531.	1.1	1
112	Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 404-411.	1.1	1
113	Alcohol consumption and prognosis in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance).. <i>Journal of Clinical Oncology</i> , 2015, 33, 1508-1508.	0.8	1
114	Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3600-3600.	0.8	1
115	Claudin 18 (<i>CLDN18</i>) gene expression and related molecular profile in gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4048-4048.	0.8	1
116	Optimizing adjuvant therapy for colon cancer: Ongoing investigations. <i>Current Colorectal Cancer Reports</i> , 2005, 1, 27-33.	1.0	0
117	Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer. <i>Hepatic Oncology</i> , 2014, 1, 331-345.	4.2	0
118	In Reply. <i>Oncologist</i> , 2018, 23, 136-136.	1.9	0
119	Effect of genetic counseling on detection of Lynch syndrome (LS) in colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, 419-419.	0.8	0
120	Racial differences in <i>KRAS</i> / <i>BRAF</i> mutation rates and survival in colon cancer (NCCTG Tj ETQqO 0 0 rgBT/Overlock 10 Tf 50	0.8	0
121	Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled analysis of 21 first-line trials in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3537-3537.	0.8	0
122	Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3585-3585.	0.8	0
123	Therapeutic impact and timing of gastrointestinal malignancy genomic profiling: A single-institution experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 584-584.	0.8	0
124	Therapeutic impact and timing of gastrointestinal malignancy genomic profiling: A single-institution experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4100-4100.	0.8	0
125	As Federal Funding for Cancer is Cut, Researchers Struggle. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, 165.	0.8	0
126	Which strategies will lead to progress in the management of colorectal cancer?. <i>Gastrointestinal Cancer Research: GCR</i> , 2007, 1, S33-6.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Gastrointestinal Cancers. , 0, , 81-104.		0
128	Using T stage to predict outcomes of adjuvant oxaliplatin (OX)-based chemotherapy (CT) in stage III colon cancer (CC): An ACCENT pooled analysis.. Journal of Clinical Oncology, 2022, 40, 3606-3606.	0.8	0
129	Molecular correlates of <i>MAEA</i> expression in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3128-3128.	0.8	0
130	Comprehensive profiling of clock genes expression in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3129-3129.	0.8	0
131	Characterization of TIM3 and its ligands in colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 3547-3547.	0.8	0
132	Comprehensive characterization of <i>PTPRT</i> expression in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3538-3538.	0.8	0
133	Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology, 2022, 40, 3553-3553.	0.8	0
134	<i>DEFB1</i> gene expression and the molecular landscape of colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3523-3523.	0.8	0
135	Landscape of endocytosis pathway in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3148-3148.	0.8	0
136	Characterization of <i>NY-ESO-1</i> gene expression in gastric cancer (GC).. Journal of Clinical Oncology, 2022, 40, 4046-4046.	0.8	0